Elon Musk’s Neuralink and OpenAI-backed Merge Labs are pushing ahead with mind–laptop interface (BCI) expertise within the U.S. In the meantime, Chinese language serial entrepreneur Phoenix Peng is constructing rival efforts by two startups: NeuroXess, which develops implantable BCI methods, and a second firm, Gestala, creating non-invasive ultrasound-based BCIs.
Gestala has raised $21.6 million (CN¥150 million) simply two months after launching, at a valuation of $100 million to $200 million, founder and CEO Phoenix Peng informed TechCrunch.
The spherical, co-led by Guosheng Capital and Dalton Enterprise with participation from Tsing Tune Capital, Gobi Ventures, Fourier Intelligence, Liepin and Seas Capital, was closely oversubscribed, with investor commitments totaling greater than $58 million, Peng added.
That is the biggest early-stage funding in China’s BCI business. Peng will use the cash in the direction of R&D, increasing the group from 15 to about 35 workers by year-end, and constructing a producing facility in China. The three-month-old startup goals to finish its first-generation prototype by the top of the 12 months.
The worldwide BCI business is presently experiencing an funding surge in ultrasound expertise. Gestala is the primary ultrasound BCI firm in China, although not the primary globally. A number of ultrasound BCI startups have emerged within the U.S. lately, together with Merge Labs, which is among the many largest.
Peng believes ultrasound may symbolize the following technology of mind–laptop interface expertise, providing the potential for broader, whole-brain entry and new methods to work together with neural exercise.
The founder says non-invasive ultrasound may handle one of many largest limitations to BCI adoption: the dangers related to mind surgical procedure. In contrast with implanted electrode methods, the expertise can monitor a bigger portion of the mind, together with deep neural circuits. Utilizing phased-array ultrasound, the system can even exactly stimulate or suppress neural exercise with out the necessity for surgical procedure, he defined.
Techcrunch occasion
San Francisco, CA
|
October 13-15, 2026
Regardless of rising geopolitical tensions, Peng nonetheless hopes the U.S. and China can collaborate on deep-technology analysis.
“Each international locations convey completely different strengths,” Peng mentioned. “China presents large-scale scientific analysis capability and environment friendly provide chains, whereas the U.S. has world-class scientific expertise.” Joint efforts may additionally give attention to constructing massive scientific datasets to assist international neuroscience analysis, he talked about.
The corporate is exploring a number of makes use of for its tech. Medically, power ache administration is the startup’s lead program. Persistent ache impacts massive populations in each the U.S. and China, and current tutorial research recommend ultrasound stimulation can considerably cut back ache ranges, Peng mentioned.
The startup can be learning purposes in psychological well being situations, together with despair, PTSD, autism and OCD, in addition to stroke rehabilitation. Different longer-term targets embrace Alzheimer’s illness, important tremor and Parkinson’s illness. In whole, the corporate is researching six to eight potential indications, although most stay on the early analysis stage fairly than in scientific trials.
Gestala says its benefit over international rivals comes down to hurry and scale. By leveraging China’s built-in manufacturing ecosystem, the startup believes it might probably transfer from improvement to manufacturing quicker than many worldwide rivals.
The corporate can be working with main Chinese language hospitals to speed up scientific trials at considerably decrease prices — roughly 20% to 33% of comparable research within the U.S. or Europe. On the similar time, Gestala is constructing what it calls an “Ultrasound Mind Financial institution,” a big scientific dataset designed to coach AI fashions to decode mind indicators and assist future neurological diagnostics.
